采血前近期接受苯达莫司汀治疗对接受嵌合抗原受体T细胞治疗的大B细胞淋巴瘤患者结局有负面影响
该多中心研究纳入7个欧洲中心的439例接受CD19靶向CAR-T治疗的复发/难治大B细胞淋巴瘤患者,其中80例采血前曾用苯达莫司汀。近期(<9个月)暴露者ORR、PFS和OS均低于未暴露者,经IPTW和PSM校正后差异仍显著;结论认为采血前近期苯达莫司汀暴露与CAR-T后不良结局相关,应避免用于CAR-T候选者。
要点
- 采血前近期(<9个月)苯达莫司汀暴露者ORR 40% vs 未暴露者72%,PFS 1.3 vs 6.2个月,OS 4.6 vs 23.5个月。
- 采血前苯达莫司汀累积剂量不影响CAR-T疗效结局。
- 作者结论认为CAR-T候选者应避免近期苯达莫司汀暴露。
核心结论
- 采血前近期苯达莫司汀暴露与CD19靶向CAR-T治疗后不良结局相关,作者认为CAR-T候选者应避免近期苯达莫司汀暴露。
研究设计与样本
- 研究纳入来自7个欧洲中心的439例接受CD19靶向商业化CAR-T治疗的复发/难治大B细胞淋巴瘤患者,其中80例采血前曾接受苯达莫司汀。
- 按采血前苯达莫司汀暴露分析安全性、疗效和CAR-T扩增动力学,并额外分析洗脱期和苯达莫司汀剂量的影响。
- 所有疗效比较均采用逆概率治疗加权(IPTW)和倾向评分匹配(PSM)分析。
主要发现
- 暴露组采血时CD3+细胞和血小板显著低于未暴露组。
- 暴露组与未暴露组相比:ORR 53% vs 72%(P < .01),PFS 3.1 vs 6.2个月(P = .04),OS 10.3 vs 23.5个月(P = .01)。
- 采用基线变量校正方法后,上述差异被减轻。
- 近期(<9个月)暴露组(N = 42)与未暴露组相比:ORR 40% vs 72%(P < .01),PFS 1.3 vs 6.2个月(P < .01),OS 4.6 vs 23.5个月(P < .01),经IPTW和PSM分析后差异仍显著。
- 采血前苯达莫司汀累积剂量不影响CAR-T疗效结局。
临床怎么用
- 作者结论认为,采血前近期苯达莫司汀暴露与CAR-T治疗后不良结局相关,应避免用于CAR-T候选者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3+ cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.
引用
- Iacoboni G, Navarro V, Martín-López AÁ, et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2023. PMID: 37874957. doi:10.1200/JCO.23.01097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。